I have the market cap at around 100m dollars.
Any ART product and I go up from there.
If you don't count the two eli 216, 154 products, you are at 22 drugs in the pipeline with the biggest in front of us.
Actavis NDA
HK Pharma NDA
HITKs 100m generic
8 Epic drugs
Pending ANDA developed in house which should be approved soon.
If we are at CFP which we have to be based on the S1 and old receiveables, then launching 3 more drugs plus soon Naltrexone too, you start to generate nice cash flow. Remember we have 1m in inventory too.
That's a PE of 6
And it doesn't account for Novel, or ART.